A general approach for the design of covalent protein proximity inducers

This project aims to expand biochemical perturbations using CoLDR chemistry to create small molecules that activate enzymes, modify PTMs, and control protein interactions for therapeutic applications.

Subsidie
€ 1.998.744
2024

Projectdetails

Introduction

Chemical biology has made remarkable strides over recent decades, producing potent and selective inhibitors for many proteins, including essential drug targets. Despite these achievements, however, inhibition has been the primary mode of perturbation (GPCRs notwithstanding), whereas many biological processes are controlled through a rich spectrum of biochemical perturbations.

Research Questions

What if a small molecule could activate an enzyme? Install or remove a post-translational modification (PTM)? Or control its oligomeric state?

Project Goals

The overarching goal of this proposal is to dramatically increase the scope and breadth of perturbations and PTMs one can induce in cells using small molecules. Accomplishing this will have tremendous impact on the ability to investigate numerous cellular processes and holds massive therapeutic potential.

Methodology

To achieve this goal, we will build on our recently developed Covalent Ligand-Directed Release (CoLDR) chemistry, which allows us to tag proteins covalently while preserving their function. Our research will develop:

  1. A general method to create CoLDR-based probes against a panel of targets, enabling us to harness their activity for selective perturbation of new, non-endogenous substrates.
  2. Homo-dimeric CoLDR probes to induce selective dimerization of targets. This will allow us to selectively activate targets such as kinases in cells. We will also design protein polymerizers by tethering obligatory homodimers.
  3. Chimeric proximity inducers that would selectively modify new targets in vitro and in cells.

Expertise

Our group’s experience in covalent chemical biology, proteolysis-targeting chimeras, and the development of the CoLDR platform makes us uniquely positioned to create the next generation of covalent proximity inducers.

Financiële details & Tijdlijn

Financiële details

Subsidiebedrag€ 1.998.744
Totale projectbegroting€ 1.998.744

Tijdlijn

Startdatum1-9-2024
Einddatum31-8-2029
Subsidiejaar2024

Partners & Locaties

Projectpartners

  • WEIZMANN INSTITUTE OF SCIENCEpenvoerder

Land(en)

Israel

Vergelijkbare projecten binnen European Research Council

ERC Starting...

Bioorthogonal Cascade-Targeting: Directing Drugs into Cells with Molecular Precision

Develop bioorthogonal cascade-targeting methods for precise, safe, and efficient intracellular delivery of therapeutics, enhancing drug targeting and minimizing collateral damage.

€ 1.479.321
ERC Starting...

Chemical rewiring of E3 ubiquitin ligases as a generalizable therapeutic approach

TrickE3 aims to systematically develop monovalent degraders to target undruggable proteins in pancreatic cancer, enhancing drug discovery and expanding the human proteome's targetable space.

€ 1.499.625
ERC Starting...

Designer Condensates for Regulation of Catalytic Processes

Develop synthetic biomolecular condensates with tunable properties from peptide libraries to enhance reaction regulation and sustainable drug synthesis in aqueous environments.

€ 1.498.750
ERC Advanced...

Protein function regulation through inserts for response to biological, chemical and physical signals

This project aims to develop a modular platform for engineering proteins to sense and respond to diverse signals, enhancing their functionality for innovative biomedical applications.

€ 2.500.000
ERC Starting...

Chemical biology of intracellular cholesterol transport

ChemBioChol aims to develop selective small molecule modulators for cholesterol transport proteins to elucidate their roles in lipid metabolism and potential therapeutic applications in diseases.

€ 1.499.786

Vergelijkbare projecten uit andere regelingen

EIC Pathfinder

Inhibitor-Mediated Programming of Glycoforms

The project aims to revolutionize glycan manipulation using Inhibitor-Mediated Programming of Glycoforms (IMProGlyco) to create precision-engineered therapeutic proteins and enhance cellular functions.

€ 2.998.878
EIC Accelerator

The ProM platform: New ways to drug the undruggable

PROSION's ProM-platform aims to unlock and target the undruggable 85% of the human proteome, developing new therapies for hard-to-treat diseases like cancer.

€ 2.461.375